Diamonds and Dogs
10/22/14Regulus Therapeutics Inc. (RGLS)
Regulus Therapeutics hit the daily double today, up 103.10% to $13.75. The biopharmaceutical company saw its shares soar after positive results from their hepatitis C drug. A single injection of a microRNA therapeutic directed at a genetic target in the liver of hepatitis C patients produced a significant drop in viral load. The drug seems to need to continue to prove itself as it needs to show an RVR off upwards of 80% to compete with current pills from Gilead Sciences. Shares of Regulus climbed nearly $7.00 to a new 52-week high of $15.38 intraday.
Willbros Group Inc. (WG)
Willbros Group is slumping today, down 35.95% to $4.90. The energy infrastructure contractor saw its shares tank after announcing its second quarter earnings results are not reliable as the found significant deterioration in a major pipeline construction project. The deterioration totals approximately $22 to $24 million and consists of the reversal of approximately $8 million in pre-tax income previously recognized by the company, as well as the recognition of an estimated $14 million to $16 million in estimated pre-tax losses at the project's completion. Shares of Willbros hit a new 52-week low of $4.82 intraday.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.